CAS: 289499-45-2; Canertinib Dihydrochloride

该化合物是一种主要用于癌症治疗的小型分子气旋激素血酶抑制剂,具体针对上皮瘤生长因子受体,以其对各种固态肿瘤的潜在效果而著称,特别是突变性肿瘤.二氯化二苯形式表明,该化合物是一种盐,提高了其溶性,加强了药物配方的稳定性.二硝基乙基的特点是,它能够抑制细胞扩散,并通过阻断肿瘤生长和存活的信号路径,在癌症细胞中诱发传染病.其化学结构包括一种五氯硝基苯核心,在乙酰丙胺抑制剂抑制剂中很常见.该化合物通常通过口服,并在临床试验中研究其处理非小型细胞肺癌,头癌和颈癌等情况的有效性.与许多有针对性的疗法一样,潜在副作用可能包括皮疹,腹泻和肝酶高,需要在治疗期间进行仔细监测.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

ECHA物质C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2024400576-A1
    优先权日:2021-09-03
    标 题:Nitrogen-containing derivatives of salinomycin, synthesis and uses thereof
    发明人：RODRIGUEZ RAPHAËL; CZERWONKA DOMINIKA; ANTOSZCZAK MICHAL; HUCZYNSKI ADAM
    权利人:CENTRE NAT RECH SCIENT; INST CURIE; INST NAT SANTE RECH MED; ADAM MICKIEWICZ UNIV
    摘要:The present invention relates to nitrogen-containing derivatives of salinomycin having the formula (I), as well as pharmaceutically acceptable salt thereof, and synthesis and uses thereof, in particular for the treatment and/or prevention of cancer including for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

    专利号:US-2025250280-A1
    优先权日:2021-09-03
    标 题 :Nitrogen-containing derivatives of narasin, synthesis and uses thereof
    发明人：RODRIGUEZ RAPHAËL; CAÑEQUE TATIANA; MÃœLLER SEBASTIAN; ANTOSZCZAK MICHAL
    权利人:CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; INST CURIE
    摘要:The present invention relates to nitrogen-containing derivatives of narasin having the formula (I), as well as synthesis and uses thereof, in particular for the treatment and/or prevention of cancer. Also disclosed are medicaments including the nitrogen-containing derivatives of narasin, which include medicaments for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

    专利号:WO-2023031399-A1
    优先权日:2021-09-03
    标题 :Iron-activable nitrogen-containing derivatives of salinomycin and narasin, synthesis and use for the treatment of cancers

    专利号:WO-2023031402-A1
    优先权日:2021-09-03
    标 题 :Nitrogen-containing derivatives of salinomycin, synthesis and uses thereof

    专利号:WO-2023031362-A1
    优先权日:2021-09-03
    标题:Nitrogen-containing derivatives of narasin, synthesis and uses thereof

    专利号:EP-4396189-B1
    优先权日:2021-09-03
    标题 :Iron-activable nitrogen-containing derivatives of salinomycin and narasin, synthesis and use for the treatment of cancers
    发明人：RODRIGUEZ RAPHAËL; CAÑEQUE TATIANA; MÃœLLER SEBASTIAN; ANTOSZCZAK MICHAL
    权利人:CENTRE NAT RECH SCIENT; INST CURIE; INST NAT SANTE RECH MED

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Galmarini CM. Canertinib pfizer. IDrugs. 2004 Jan;7(1):58-63.
    328:59-66. doi: 10.1016/j.heares.2015.07.002. Epub 2015 Jul 7.
    3: Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20. doi: 10.1016/j.jaad.2014.07.032.

    合成参考文献


    参考文献:10.1385/1-59745-012-x:189
    摘要:Chinnaiyan P, Harari PM. Clinical advancement of EGFR inhibitors in cancer therapy. Methods Mol Biol. 2006;327():189–202. doi: 10.1385/1-59745-012-x:189.
    参考文献:10.1186/bcr919
    摘要:Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004;6(5):204–10.
    参考文献:10.1007/s10354-006-0308-3
    摘要:Hutterer M, Gunsilius E, Stockhammer G. Molecular therapies for malignant glioma. Wien Med Wochenschr. 2006 Jun;156(11-12):351–63. doi: 10.1007/s10354-006-0308-3.
    参考文献:10.1007/s10555-008-9148-5
    摘要:Nimmagadda S, Shields AF. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer and Metastasis Reviews. 2008 May 30;27(4):575–87. doi: 10.1007/s10555-008-9148-5.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知